
MD | Medical Oncologist | Alumni @Hacettepe1967 @AnkaraUni | 2024 ASCO IDEA awardee | #cat lover
Türkiye
Joined August 2018
- Tweets198
- Following327
- Followers467
- Likes910
Pinned Tweet
Our review on DDIs in prostate Ca is now published @ESMO_Open! @coskunyazgann
Thanks to @DrYukselUrun @Silke_Gillessen @DrRanaMcKay @yekeduz_emre and Marina Kaymakcalan for their support.
authors.elsevier.com/sd/arti…
Hatice Bölek retweeted
VOLGA: OS benefit without adjuvant EV.
Do we really need EV after surgery? An important question for future trials.
Proud to have contributed to this study.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @Uromigos @urologysummit
Hatice Bölek retweeted
Availability is not access.
Proud to lead our ARON-AID study: revealing major gaps in kidney cancer treatment access across 58 countries.
Grateful to all our collaborators for this truly global effort.
How can we close this gap?
@OncJournal @OncoAlert @OpenMedicineHQ @KidneyCancer @kidneycan @IKCCorg @ASCO @myESMO @urologysummit
Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial
@EUplatinum
europeanurology.com/article/…
1
127
New ESMO Guideline on Cervical Cancer
🔹 Less invasive surgery in early-stage disease: following SHAPE, simple hysterectomy is recommended for selected low-risk tumors ≤2 cm. For tumors <4 cm, SLNB is now the preferred method of LN staging.
🔹 Even with negative imaging, para-aortic LN metastases may be present in 8–12% of LACC, imaging sensitivity %33-62
🔹 INTERLACE was positive, but induction chemotherapy is recommended only when IMRT/VMAT and/or IGABT are unavailable.
🔹 HRT >> part of survivorship care for premenopausal women.
@myESMO
esmoopen.com/action/showPdf?…
1
8
355
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
thelancet.com/journals/lance…
1
6
807
Redefining therapy for previously treated renal cell carcinoma
Accompanying comment by @DrRanaMcKay
thelancet.com/journals/lance…
81
Hatice Bölek retweeted
👀Whoat! A trivia #ASCO26? Who's in?
Love this idea! Looking forward to some friendly competition and team building while having fun through @oncology questions and fun facts! 🤓
🙋♀️See you at 2.30 pm at @ASCO TEC Lounge! @ASCOTECAG
#MedEd @OncMedEdCoP @vincedcataldo @IMG_Oncologists @OncoAlert @kor_shah @ja_ocejo @Noha_Soror @ASridharMD @FionnualaCrowle @thenasheffect @OncBrothers @TwoOncDocs @DrKarineTawagi @OncoAlert @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @jgong15 @DrSAHaddad @GIMedOnc @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc @montypal @neerajaiims @yekeduz_emre @DrYukselUrun @imdat_eroglu @hatice_bolek
📣📣📣
Calling all trainees at #ASCO26!
Face off against other teams of trainees from across the globe to test your Medical Oncology knowledge in this team trivia event!
Date: Friday, May 29
Time: 2:30PM – 3:45PM CT
Location: Trainee & Early Career Lounge
Hatice Bölek retweeted
Our new international real-world validation of the Meet-URO score in 1,418 first-line mRCC patients is out in @TOncologist.
Read here: doi.org/10.1093/oncolo/oyag2…
#OncTwitter #KidneyCancer #mRCC #PrecisionMedicine
📣 Sac-TMT demonstrated improved OS and PFS compared with chemotherapy in advanced/recurrent endometrial cancer previously treated with platinum-based chemotherapy and anti-PD-1/L1 immunotherapy!
A new option in a setting with limited treatment options.
Hatice Bölek retweeted
Happy to see our work cited at APCCC.
ARPI selection in older patients is not only efficacy.
Drug interactions, comorbidities, and daily medications matter.
@hatice_bolek @yekeduz_emre @myESMO @ESMO_Open
@OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @CaPsurvivorship @NehaVapiwala @piet_ost
Hatice Bölek retweeted
Seeing your mentee featured by @myESMO is something else.
Dr. Hatice Bölek, top performers.
That’s the work paying off.
Proud. 🙌 @hatice_bolek @OncoAlert @Ankaratip1945 @AnkaraUni
📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST.
📍Onsite in Madrid + selected locations.
⏳Early fee ends 28 Apr.
🔗 Secure your seat: ow.ly/JWMq50YAGgM
Very happy to see this post by @myESMO.
📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST.
📍Onsite in Madrid + selected locations.
⏳Early fee ends 28 Apr.
🔗 Secure your seat: ow.ly/JWMq50YAGgM
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer @ASCO
ascopubs.org/doi/10.1200/EDB…
Our correspondence on the LUNAR trial is now published in JCO.
@DrYukselUrun @JCO_ASCO
ascopubs.org/doi/10.1200/JCO…
Hatice Bölek retweeted
Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), ⬆️ RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still don’t have significant OS post in IO refractory RCC @OncoAlert
An Editorial on a Clinical Grey Zone: cN+ M0 Bladder Cancer
Regional Node–positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings
europeanurology.com/article/…
@EUplatinum @PGrivasMDPhD
Hatice Bölek retweeted
Huge congrats to brilliant mentees @hatice_bolek @coskunyazgann and mente/mentor @yekeduz_emre
Big thanks to @DrChoueiri @montypal @BradMcG04 and @DrRanaMcKay for their outstanding contributions, guidance, and support!
🔑IO rechallenge + VEGF TKI no survival gain in mRCC.
@OncJournal @OncoAlert @Ankaratip1945 @AnkaraUni @IKCCorg @kidneycan @KidneyCancer @Uromigos
doi.org/10.1093/oncolo/oyaf4…
Hatice Bölek retweeted
Proud mentor moment.
Heartfelt congrats, Hatice!
This success is not luck.
The future is bright!
@myESMO @hatice_bolek @onkolojidernegi
It was a great experience to participate in the @myESMO Preceptorship on Prostate Cancer and to present a case in the session chaired by my mentor, @DrYukselUrun
If you haven’t attended before, you should definitely consider joining next year.




























